Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amneal pharmaceuticals inc - AMRX

AMRX

Close Chg Chg %
12.26 -0.20 -1.63%

Closed Market

12.06

-0.20 (1.63%)

Volume: 881.12K

Last Updated:

Mar 26, 2026, 4:00 PM EDT

Trade Now

Company Overview: amneal pharmaceuticals inc - AMRX

AMRX Key Data

Open

$12.14

 Day Range

12.00 - 12.26

52 Week Range

6.69 - 15.42

 Market Cap

$3.86B

Shares Outstanding

314.63M

 Public Float

156.91M

Beta

1.35

 Rev. Per Employee

N/A

P/E Ratio

55.28

 EPS

$0.23

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.56M

  

AMRX Performance

1 Week
 
 3.63%
 
1 Month
 
 -11.22%
 
3 Months
 
 -5.33%
 
1 Year
 
 48.07%
 
5 Years
 
 78.98%
 

AMRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About amneal pharmaceuticals inc - AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX At a Glance

Amneal Pharmaceuticals, Inc.
400 Crossing Boulevard
Bridgewater, New Jersey 08807
Phone 1-908-947-3120 Revenue 3.02B
Industry Pharmaceuticals: Major Net Income 72.06M
Sector Health Technology 2025 Sales Growth 8.046%
Fiscal Year-end 12 / 2026 Employees 8,500
View SEC Filings

AMRX Valuation

P/E Current 54.418
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 56.808
Price to Sales Ratio 1.356
Price to Book Ratio N/A
Price to Cash Flow Ratio 12.04
Enterprise Value to EBITDA 10.125
Enterprise Value to Sales 2.169
Total Debt to Enterprise Value 0.411

AMRX Efficiency

Revenue/Employee 355,148.235
Income Per Employee 8,477.294
Receivables Turnover 3.212
Total Asset Turnover 0.841

AMRX Liquidity

Current Ratio 2.168
Quick Ratio 1.48
Cash Ratio 0.353

AMRX Profitability

Gross Margin 37.634
Operating Margin 14.015
Pretax Margin 4.611
Net Margin 2.387
Return on Assets 2.007
Return on Equity N/A
Return on Total Capital 2.752
Return on Invested Capital 3.04

AMRX Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 102.704
Total Debt to Total Assets 73.106
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 101.88
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amneal Pharmaceuticals Inc - AMRX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.21B 2.39B 2.79B 3.02B
Sales Growth
+5.67% +8.20% +16.73% +8.05%
Cost of Goods Sold (COGS) incl D&A
1.42B 1.54B 1.77B 1.88B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
240.18M 229.40M 236.19M 223.57M
Depreciation
68.11M 66.20M 62.60M 57.30M
Amortization of Intangibles
172.06M 163.20M 173.59M 166.27M
COGS Growth
+8.79% +8.50% +15.39% +6.15%
Gross Income
795.82M 856.66M 1.02B 1.14B
Gross Income Growth
+0.52% +7.65% +19.12% +11.33%
Gross Profit Margin
+35.97% +35.79% +36.52% +37.63%
2022 2023 2024 2025 5-year trend
SG&A Expense
595.39M 593.63M 667.15M 713.00M
Research & Development
195.69M 163.95M 190.71M 186.18M
Other SG&A
399.70M 429.68M 476.44M 526.83M
SGA Growth
+4.94% -0.30% +12.39% +6.87%
Other Operating Expense
- - - -
-
Unusual Expense
299.61M 100.61M 103.96M 65.60M
EBIT after Unusual Expense
(99.18M) 162.43M 249.33M 357.49M
Non Operating Income/Expense
9.43M 7.93M (45.74M) 22.81M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
158.38M 210.63M 258.60M 241.09M
Interest Expense Growth
+16.18% +32.99% +22.77% -6.77%
Gross Interest Expense
158.38M 210.63M 258.60M 241.09M
Interest Capitalized
- - - -
-
Pretax Income
(248.13M) (40.27M) (55.01M) 139.21M
Pretax Income Growth
-891.07% +83.77% -36.61% +353.05%
Pretax Margin
-11.22% -1.68% -1.97% +4.61%
Income Tax
6.66M 8.45M 18.86M 11.28M
Income Tax - Current - Domestic
(1.07M) 2.47M 8.31M (186.00K)
Income Tax - Current - Foreign
7.74M 5.98M 10.55M 11.46M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(254.79M) (48.72M) (73.88M) 127.93M
Minority Interest Expense
(124.80M) 35.27M 43.01M 55.88M
Net Income
(129.99M) (83.99M) (116.89M) 72.06M
Net Income Growth
-1,323.51% +35.38% -39.16% +161.65%
Net Margin Growth
-5.88% -3.51% -4.18% +2.39%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(129.99M) (83.99M) (116.89M) 72.06M
Preferred Dividends
- - - -
-
Net Income Available to Common
(129.99M) (83.99M) (116.89M) 72.06M
EPS (Basic)
-0.8612 -0.4769 -0.3783 0.2299
EPS (Basic) Growth
-1,307.85% +44.62% +20.68% +160.77%
Basic Shares Outstanding
150.94M 176.14M 308.98M 313.37M
EPS (Diluted)
-0.8612 -0.4769 -0.3783 0.2218
EPS (Diluted) Growth
-1,330.29% +44.62% +20.68% +158.63%
Diluted Shares Outstanding
150.94M 176.14M 308.98M 324.81M
EBITDA
440.61M 492.44M 589.48M 646.66M
EBITDA Growth
-3.74% +11.76% +19.71% +9.70%
EBITDA Margin
+19.92% +20.57% +21.10% +21.42%

Snapshot

Average Recommendation BUY Average Target Price 16.40
Number of Ratings 5 Current Quarters Estimate 0.164
FY Report Date 03 / 2026 Current Year's Estimate 0.99
Last Quarter’s Earnings 0.21 Median PE on CY Estimate N/A
Year Ago Earnings 0.83 Next Fiscal Year Estimate 1.176
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate 0.16 0.23 0.99 1.18
High Estimates 0.17 0.25 1.00 1.22
Low Estimate 0.15 0.21 0.98 1.11
Coefficient of Variance 5.45 6.39 0.71 3.74

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 4
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Amneal Pharmaceuticals Inc - AMRX

Date Name Shares Transaction Value
Mar 6, 2026 Andrew S. Boyer Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Jason B. Daly EVP, Chief Legal Officer 71,760 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Anastasios G. Konidaris Executive Vice President & CFO 212,886 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Anastasios G. Konidaris Executive Vice President & CFO 184,348 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.31 per share 2,453,671.88
Mar 6, 2026 Anastasios G. Konidaris Executive Vice President & CFO 208,599 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Anastasios G. Konidaris Executive Vice President & CFO 151,260 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.31 per share 2,013,270.60
Mar 6, 2026 Anastasios G. Konidaris Executive Vice President & CFO 167,442 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 76,389 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 72,774 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 49,695 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 191,678 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 426,072 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.3 per share 5,666,757.60
Mar 6, 2026 Andrew S. Boyer Executive Vice President 445,208 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 407,013 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.31 per share 5,417,343.03
Mar 6, 2026 Andrew S. Boyer Executive Vice President 606,188 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 208,634 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.31 per share 2,776,918.54
Mar 6, 2026 Andrew S. Boyer Executive Vice President 220,788 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Andrew S. Boyer Executive Vice President 196,530 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.31 per share 2,615,814.30
Mar 6, 2026 Andrew S. Boyer Executive Vice President 221,427 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Amneal Pharmaceuticals Inc in the News